LDN-212854 [1432597-26-6]
Référence T1900-5mg
Conditionnement : 5mg
Marque : TargetMol
LDN-212854
(Synonyms: LDN212854, BMP Inhibitor III) Copy Product InfoLDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.
Select Batch
Purity:98.71%
Color:White
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors. |
| Targets & IC50 | BMPR1A:85.8 nM, ALK1:2.4 nM, ALK4:2133 nM, ALK5:9276 nM, ALK2:1.3 nM |
| In vitro | LDN-212854 (6 mg/kg, i.p.) effectively inactivates ALK2 signaling in vivo and efficiently inhibits ectopic ossification in inducible transgenic ALK2 mice mutants with progressive ankylosis. |
| In vivo | In C2C12 myoblasts, LDN-212854 demonstrates a higher selectivity for BMP6 over BMP4 in inducing osteogenic differentiation, compared to the osteogenic differentiation induced by BMP6 and BMP4. |
| Synonyms | LDN212854, BMP Inhibitor III |
| Molecular Weight | 406.48 |
| Formula | C25H22N6 |
| Cas No. | 1432597-26-6 |
| Smiles | C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12 |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10.42 mg/mL (25.63 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||




